Versa Vascular

About Versa Vascular

Established in 2020, Versa Vascular is a medical technology company that emerged from the Santa Cruz MedTech incubator, Occam Labs. The company was founded by a team with extensive experience in structural heart catheters and implants, including Dan Wallace, who serves as Founder and CTO. Their mission is to address the unmet clinical need for treating tricuspid regurgitation (TR), a condition where the heart's tricuspid valve doesn't close properly.

Versa Vascular is developing a minimally invasive, catheter-based system to repair the native tricuspid valve. The device, which consists of a permanent implant and a delivery system, is designed to be deployed percutaneously through the femoral vein. A key feature of the implant is that it sits entirely in the right atrium with low radial force, working in conjunction with the native leaflets to improve blood flow without interfering with the sub-valvular apparatus. This approach is intended for patients with severe TR who are considered poor candidates for open-heart surgery.

The company operates as a nimble entity within the Occam Labs ecosystem, leveraging a broader pool of knowledge and experience. In July 2025, Versa Vascular announced it had closed an oversubscribed funding round of $27.3 million to advance its pre-pivotal trials and expand its leadership team. Early human trials have shown promising results, with notable improvements in patient renal function and walking endurance without device-related adverse events. The business model focuses on developing and bringing this specialized medical device to the structural heart market, competing with other systems in the tricuspid repair space.